Drugs / AAVAnc80-antiVEGF
AAVAnc80-antiVEGF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06517888 | Jan 2025 → Aug 2029 expected | acoustic neuroma | Akouos, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVAnc80-antiVEGF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06517888 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAVAnc80-antiVEGF Gene Therapy” NCT06517888 ↗ |
| Route | Other | “intracochlear administration” NCT06517888 ↗ |